Código QR (código de barras bidimensional)

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Abstract Background Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may more closely align with cardiovascular risk than low-density lipoprotein cholesterol (LDL-C). We describe the design and rationale o...

ver descrição completa

Na minha lista:
Principais autores: Dirk Müller-Wieland, Lawrence A. Leiter, Bertrand Cariou, Alexia Letierce, Helen M. Colhoun, Stefano Del Prato, Robert R. Henry, Francisco J. Tinahones, Lisa Aurand, Jaman Maroni, Kausik K. Ray, Maja Bujas-Bobanovic
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2017-05-01
coleção:Cardiovascular Diabetology
Assuntos:
Alirocumab
PCSK9
Diabetes
Mixed dyslipidaemia
Non-HDL-C
ODYSSEY
Acesso em linha:http://link.springer.com/article/10.1186/s12933-017-0552-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados